Trainings

The Program runs many events to train current and future leaders in Global Health,  including:

IMG_0042

The Global Health Fellows Program, a track of the Program on Global Policy and Governance, takes place every summer in Geneva, Switzerland. It attracts 20-30 of the best and brightest future leaders in global health to take part in 8-10 week internships at organizations in Geneva. It also holds one week-long, policy intensive course that includes 25 expert led seminar sessions and site visits to key policy venues in Geneva.

The 2013 cohort learned from speakers on topics ranging from Innovation + Access, Systems Thinking, and Universal Health Coverage to Noncommunicable Diseases, Malaria Treatment and Scale-up, Violence & Injury Prevention, and Mental Health. They also visited sites including the WHO Polio Eradication Initiative, the Global Fund to Fight AIDS, Tuberculosis, & Malaria, Médecins San Frontières, and the GAVI Alliance, and attended the Symposium on Changing Business Models at the World Intellectual Property Organization and heard a join address by the Director Generals of the World Health Organization, World Trade Organization & the World Intellectual Property Organization. Those interested in applying should visit http://graduate.sanford.duke.edu/geneva/health.


IMG_0206

The Program hosted the first annual Knowledge for Global Health (K4GH) Leadership Institute alongside the American Medical Student Association (AMSA). The Institute aimed to:Create a network of students from various disciplines to develop solutions for sustainable innovation and affordable access to health technologies and research

  • Provide core training on policy issues of sharing knowledge including research and educational resources, access to medicines and access to knowledge
  • Create working groups for strategizing over potential challenges and campaigns in these areas
  • Build a critical student mass that would mobilize around several follow-on targets of opportunity

The three day convening had policy training sessions led by current scholars and activists aimed to equip future leaders with tools to organize and lead future initiatives. It also had problem smashing breakout sessions on Innovation + Access, Antibiotic Defense, and Open Access.

As part of Dr. So’s graduate seminar on “Designing Innovation for Global Health,” a special day-and-a-half symposium was held on April 6-7, 2012. Recognizing the need for new models to develop and adapt health innovations for resource-limited settings, the OpenSCI 2012 Conference explored various types of collaborative models for bringing health technologies and interventions from bench to bedside. The OpenSCI Conference opened with four sessions that explored the potential of collaboration in three areas—cooperation among scientists, non-scientists (“citizen scientists”), and end-users in resource-limited settings (the Base of the Pyramid).

In 2007, the GHTA Program co-organized with the American Medical Student Association Foundation the inaugural Pharmaceutical Policy Leaders in Medicine Institute. Training twenty physicians-in-training, the four-day Institute provided intensive training and interaction with some of the leading change makers, researchers and journalists reporting on pharmaceutical policy. Some of the speakers included Dr. Stephen Cha, Legislative Aide to Congressman Henry Waxman’s Committee on Oversight and Government Reform, who will speak about handling the Congressional hearings on the FDA’s assessment of the safety of Avandia; journalist and psychiatrist Dr. Miriam Shuchman, National Correspondent for the New England Journal of Medicine and author of the award-winning book, The Drug Trial: Nancy Olivieri and the Science Scandal That Rocked the Hospital for Sick Children; Robert Weissman, Co-Director of Essential Action and editor of Multinational Monitor magazine, who has done significant work on transparency in the pharmaceutical sector; and Dr. Peter Lurie, Deputy Director of Public Citizen’s Health Research Group, who has successfully petitioned the FDA and CMS to challenge ineffective medical devices and drugs.